Small peptides having potent anti-angiogenic activity

Details Small peptides having potent anti-angiogenic activity Small peptides having potent anti-angiogenic activity

1999-08-30

2001-03-13

Moezie, F. T. (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C514S015800, C514S016700, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000, C530S350000, C536S063000, C435S069100, C435S242000, C435S252300, C435S254110, C435S320100

Reexamination Certificate

active

06200954

ABSTRACT:

FIELD OF THE INVENTION
The invention involves small peptides that function as potent angiogenic inhibitors. In particular, the invention relates to small peptides that can be synthesized by enzymatic or chemical methods. In addition, the invention relates to use of the small peptides to inhibit angiogenesis, to treat angiogenesis-related diseases and in angiogenesis research.
BACKGROUND OF THE INVENTION
Angiogenesis is the process of new blood vessel formation from pre-existing vessels. It plays important roles in many normal physiological functions such as embryonic development and wound healing (1). In addition, inappropriate angiogenesis is also associated with various pathological conditions including solid tumor growth and metastasis, rheumatoid arthritis and psoriasis (2). Many molecules that inhibit tumor angiogenesis have been shown to inhibit tumor growth including antibodies against angiogenic factors, natural and synthetic compounds that inhibit angiogenesis, and the natural angiogenic inhibitors like the angiostatin and endostatin proteins produced by tumor cells (3-8). Anti-cancer therapy by inhibiting tumor angiogenesis is called anti-angiogenic therapy and has shown great potential as an effective new method for treating cancer, especially solid tumors (9).
Plasminogen is a plasma glycoprotein synthesized mainly in the liver. It is the precursor of the serum protease plasmin that plays important roles in the fibrinolytic system and clot dissolution (10). At the amino terminus, plasminogen contains five homologous repeats that form looped “kringle” structures held together by disulfide bonds. Plasminogen binds to fibrin through lysine binding sites located on the five kringle domains (k1 through k5) (10). A naturally occurring fragment of plasminogen containing the first four kringle domains (k1-k4) has been isolated from serum and urine of mice bearing a low metastic Lewis lung carcinoma. This plasminogen fragment has been named angiostatin (equivalent to amino acids 98-440 of murine plasminogen) and is a potent angiogenesis inhibitor that can inhibit endothelial cell proliferation as well as tumor growth and metastasis in mice with no obvious toxicity (5, 6, 11). Furthermore, recombinant individual kringle domains of human plasminogen produced in
E. coli
have been found to be able to inhibit endothelial cell proliferation to various degrees with k5 the most potent, followed by k1 and k3 (12, 13). The k5 domain is not present in the naturally existing angiostatin protein.
Endostatin is a protein first identified from a hemangioendothelioma cell line in 1997 (17). It is a 20 kDa C-terminal fragment of collagen XVIII, a novel collagen that consists of a N-terminal region, a series of collagen-like domains with interruptions and a 35 kDa C-terminal noncollagenous domain (18, 19, 20). Recombinant endostatin functions as a potent angiogenesis inhibitor in vitro as well as in vivo (17). Systemic administration of endostatin to tumor bearing mice regressed the primary tumor without inducing drug resistance (21). Recently, endostatin was found to be a zinc-binding protein and the zinc-binding is essential for its antiangiogenic activity (22, 23). Human trials of endostatin are expected to be undertaken.
Vascular Endothelial Growth Factor (VEGF) is a potent endothelial specific mitogen. VEGF functions through two high affinity tyrosine kinase receptors: FLT-1 or Vascular Endothelial Growth Factor Receptor type 1 (FLT-1/VEGFR1) and FLK-1, also known as KDR or Vascular Endothelial Growth Factor Receptor type 2 (FLK-1/VEGFR2) and FLK-1/VEGFR2 (26). Both receptors are specifically expressed in endothelial cells. FLT-1 and KDR/FLK-1 stimulate endothelial cell proliferation and migration by binding to these two tyrosine kinase receptors (24). VEGF is also known as vascular permeability factor due to its ability to induce vascular leakage (24). The ligand binding domains of the two receptors as well as the receptor binding sites of VEGF have been studied by site-directed mutagenesis and X-ray crystallography (25, 26, 27, 28). VEGF binds its two receptors through different amino acid contacts (25). The first three immunoglobulin loops of the FLT-1 receptor seem to be the main area responsible for VEGF binding (29, 30). The signal transduction triggered by VEGF through its receptors play critical roles in both physiological angiogenesis as well as pathological angiogenesis such as solid tumor growth and metastasis by stimulating embryonic angiogenesis and tumor angiogenesis. An anti-VEGF monoclonal antibody has been shown to inhibit tumor growth in mice by reducing the vessel density of the tumor (14). Likewise, trans-dominant mutants of both receptors have been shown to inhibit tumor growth in mice (15).
It has also been observed that proline residues are sometimes found at the ends of the linear sequences that constitute the site of a protein-protein interaction (14, 15). However, the proline residues are not usually present within the interaction site.
SUMMARY OF THE INVENTION
The invention provides compositions comprising the peptides that are effective in inhibiting undesirable angiogenesis. The invention includes small peptides that have the ability to inhibit bovine aorta endothelial cell proliferation in the presence of basic Fibroblast Growth Factor (bFGF) in vitro. They can also inhibit angiogenesis in the chick chorioallantoic membrane (CAM) in vivo. The peptides of the invention are typically less than 20 amino acids in length. They preferably contain proline residues at each end or penultimate thereto. Peptides of the invention can be identified within the kringle domains of plasminogen or within the amino acid sequences of endostatin, VEGF, and VEGF receptors, especially FLT-1 and KDR/FLK-1.
Some preferred peptides of the invention are named Angio-1, Angio-2, Angio-3, Angio-4 and Angio-5 (SEQ. ID. NOs. 1-3, 11 and 12) according to the plasminogen kringle domains they are derived from. Other preferred peptides are shown in Table 1 (SEQ ID NOS. 29-50).
Methods for preventing or treating undesirable angiogenesis, for example to prevent tumor metastasis or inhibit the growth of a primary tumor, by administration of compositions of the anti-angiogenic peptides, are also within the scope of the invention.


REFERENCES:
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5712380 (1998-01-01), Kendall
Wiesmann et al., Crystal Structure at 1.7 ↑ Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor Cel. vol. 91, 695-704, Nov. 28, 1997.
Judah Folkman et al, Cell, vol. 87, 1153-1156, Dec. 27, 1996.
Judah Folkman et al., Nature Medicine, vol. 1, No. 1, pp. 27-31 1999.
K. Jin Kim et al, Nature vol. 362, pp. 841-844, Apr. 29, 1993.
Judah Folkman, Cell. vol. 79, 315-328, Oct. 21, 1994.
Michael S. O'Reilly et al, Nature Medicine, vol. 2, No. 6, pp. 689-692 Jun. 1996.
Michael S. O'Reilly et al, Cell, vol. 88, 277-285, Jan. 24, 1997.
Thomas Boehm et al, Nature vol. 390 (27), pp. 404-407 Nov. 1997.
Robert S. Kerbel, Nature vol. 390 (27), pp. 335-336 Nov. 27, 1997.
Robert Handin et al, Heart Disease, A Textbook of Cardiovascular Medicine, Fourth Edition, pp. 1767-1789, 1992.
Birgit Millauer et al, Nature, vol. 367, pp. 576-579 Feb. 10, 1994.
Yihai Cao et al, The Journal of Biological Chemistry vol. 271, No. 46, pp. 29461-29467, 1996.
R. Manjunatha Kini et al, Current Topics in Peptide & Prot. Res. 1, pp. 297-311 (1994).
R. Manjunatha Kini et al, Biochemical and Biophysical, vol. 212, No. 3, 1995, Jun. 26, 1995, pp. 1115-1124.
Suk Paul Oh et al, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 4229-4233, May 1994.
Marko Rehn et al, Proc. Natl. Acad. Sci. USA. vol. 91, pp. 4234-4238, May 1994.
Y. Muragaki et al, Proc. Natl., Acad. Sci, USA. vol. 92, pp. 8763-8767, Sep. 1995.
Yuan-Hua Ding et al., Proc. Natl., Acad. Sci. USA vol. 95, pp. 10443-10448, Sep. 1998.
Thomas Boehm et al, Biochemistry and Biophysical Research Comm. 252, pp. 190-194, (1998).
Napoleone Ferrara et al, Endocrine Reviews vol. 18, No. 1, pp. 4-24, 1997.
Bruce A. Keyt et al, The Journal of B

Affiliated with

Also associated with

Rating

Small peptides having potent anti-angiogenic activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Small peptides having potent anti-angiogenic activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small peptides having potent anti-angiogenic activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2545388